Merck provided some of the clearest direction yet regarding its ambitions in oncology to improve on its blockbuster immunotherapy Keytruda.
Merck provided some of the clearest direction yet regarding its ambitions in oncology to improve on its blockbuster immunotherapy Keytruda.
The company plans to conduct …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth…
An experimental antibody-drug conjugate from Merck and Kelun-Biotech succeeded in a global Phase 3 study for the first time,…
The clinical blueprint for Merck & Co.’s prized TROP2-directed antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), could…
Investors have bet new drugs can topple Merck’s Keytruda, but the evidence so far points to something smaller.
The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,”…
Over the last 18 months, Merck and Kelun-Biotech have notched four approvals in China for their TROP2-directed antibody-drug…
